Altmetrics
Downloads
104
Views
52
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.pdf (548.71KB )
This version is not peer-reviewed
Submitted:
13 September 2024
Posted:
14 September 2024
You are already at the latest version
Location/ Country |
Type of Study | HB/CB/ OTP |
Study period | Study population | Sample size (n) | Age range or Median age | Number of Pathogens/Infection cases (n) | Fatality rates | Authors/Year of publication | No. of reference | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
South Africa | Prospective, observational study | HB | NS | SAM | 113 | < 5 years | HIV (n=58), TB (n=27) | 11.5% (n=13) | De Maayer et al 2011 | [13] | |||||||
aEthiopia | Retrospective cohort study | HB | 2013 to 2015 | SAM | 545 | < 5 years | Malaria (n=37), TB (n=41) |
9.3% (n=51) | Girum et al 2017 | [14] | |||||||
Sierra Leone | Descriptive cross-sectional study | HB | Over 6 months in 2018 | SAM | 74 | Median age of 11 months | TB (n=20) | - | Ide et al, 2019 | [15] | |||||||
Zambia | Retrospective study | HB | 2009 to 2013 | SAM | 9,450 | 0 to 59 months | TB (n=151) | 56% (n=84) | Munthali et al 2017 | [16] | |||||||
Mozambique | Retrospective study | HB | February to August 2018 | SAM | 45 | 0 to 59 months | TB (n=17) | - | Osorio et al. 2020 | [17] | |||||||
aSouth Africa | Cross-sectional study | HB | 2014 – 2018 | SAM | 956 | Children under 5 years | HIV (n=181) TB (n=127) Malaria (n=4) |
25.9% (n=248) | Gavhi et al.2019(2020) | [18] | |||||||
Uganda | Cross-sectional study | HB | June 2021 to December 2022 | SAM | 797 | 1 month to 5 years | HIV (n=76) | - | Musiime et al. 2024 | [19] | |||||||
bZambia/ Zimbabwe |
Prospective cohort study | HB | July 2016 and March 2019 | SAM | 649 | 1 to 59 months | HIV (n=130) | 8.5% (n=55) | Bwakura-Dangarembizi et al, 2021 | [20] | |||||||
Malawi | Prospective cohort study | HB | NS | SAM | 454 | 6 to 59 months | HIV (n=79) | 14.8% (n=67) | Chinkhumba et al, 2008 | [21] | |||||||
aNiger | Prospective study | HB | November 2007 to July 2008 | Complicated SAM | 311 | 6 to 59 months | Bacteremia, n=79, malaria parasite, n=44, enteric pathogens isolated from stool (bacteria, n=36, viruses, n=23, intestinal parasites, n=6), TB (n=4), pathogens isolated from the urinary tract (bacteria, n=48), pathogens identified from nasal swabs (viruses, n=5) | 9% (n=29) | Page et al, 2013 | [22] | |||||||
Mozambique | Retrospective observational study | HB | March 2016 to February 2017 | SAM | 1,231 | 0 to 5 years | HIV (n=157) | - | Calgaro et al, 2021 | [23] | |||||||
Ethiopia | Cross-sectional study | HB | April – June 2020 | SAM | 208 | 6 to 59 | HIV (n=11) | - | Teshale et al, 2023 | [24] | |||||||
aEthiopia | Retrospective cohort study | HB | January 2012 to December 2015 | SAM | 500 | Under 5 years | TB (n=15) | 7% (NS) | Yohannes et al, 2017 | [25] | |||||||
aMozambique | Cross-sectional study | HB | January 2018 to March 2020 | Undernourished children | 449 | 1 to 14 years | HIV (n=120), malaria (n=12), intestinal parasitic infections (n=90) | - | Cossa-Moiane et al, 2024 | [26] | |||||||
Zambia | Retrospective study | CB | October 2009 and September 2012 | SAM (n=1,195) MAM (n=664) | 1,859 | Median age of 16 months | HIV in children with SAM (n=134) HIV in children with MAM (n=51) |
2.9% (n=53) | Amadi et al, 2016 | [27] | |||||||
aSouth Africa | Retrospective cohort study | HB | October 2014 to December 2018. | SAM | 126 | 0 to 59 months | HIV (n=23), TB (n=17) | 15.1 % (n=19) | Heydenrych et al, 2024 | [28] | |||||||
aGhana | Cross-sectional prospective study | HB | February 2010 to October 2010 | SAM | 246 | 3 months to 13 years | HIV (n=67), TB (n=23), malaria (n=34), bacteremia (n=85) | 17.5% (n=43) | Asafo-Agyei et al 2013 | [29] | |||||||
aEthiopia | Retrospective follow-up study | HB | March to April, 2018 | SAM | 398 | 6 to 59 months | HIV (n=1), malaria (n=76), TB (n=27) | - | Wondim et al, 2020 | [30] | |||||||
aEthiopia | Retrospective cohort study | HB | September 2017 to March 2020. | Complicated SAM | 665 | 0 to 59 months | HIV (n=5), TB (n=23), malaria (n=2) | 9% (60) | Oumer et al, 2021 | [31] | |||||||
Sudan | Prospective hospital-based study | HB | April to October 2018 | SAM | 376 | 6 to 59 months | Malaria (n=131), intestinal parasites (n=24) | 3.7% (n=14) | Bilal et al, 2020 | [32] | |||||||
Kenya | Prospective descriptive study | HB | June 2005 to June 2009 | SAM | 1,206 | 6 to 12 years | HIV (n=229), malaria parasitemia (n=227), bacteremia (n=86) | 16% (194) | Talbert et al, 2012 | [33] | |||||||
Malawi | Cross-sectional observational study | HB | February to May 2012 | SAM | 300 | 6 to 60 months | HIV (n=52), TB (n=2) | 9.7% (n=29) | LaCourse et al. 2014 | [34] | |||||||
bKenya/Tanzania | A retrospective study | HB | 2004 to 2005 | SAM | 1121 | NS | Malaria (n=404), candidiasis (n=119), TB (n=293) | 19% (n=64) 28% (n=222) |
Sunguya et al, 2006 | [35] | |||||||
Niger | Cross-sectional study | HB | 2016 to 2017 | SAM | 202 | < 5 years | TB (n=90) | 19.6% (n=20) | Schramm et al. 2021 | [36] | |||||||
aUganda | Prospective study | HB | September-November 2003 and September-December 2004 | SAM | 450 | < 60 months | HIV (n=151), bacteremia (n=76) | 28.9% (n=22) | Bachou et al, 2006 | [37] | |||||||
Zambia | Retrospective | CB | 2012 to 2014 | SAM | 858 | 6 to 59 months | HIV (n=63), malaria (n=7) | 5.6% (n=48) | Moramarco et al, 2016 | [38] | |||||||
Nigeria | Cross-sectional study | HB | - | SAM | 400 | < 5 years | HIV (n=31) | - | Sudawa et al, 2013 | [39] | |||||||
aEthiopia | Retrospective cross-sectional study | HB | 2018 – 2020 | SAM | 414 | < 5 years | Malaria (n=7), HIV (n=20), TB (n=43) | - | Atalell et al, 2021 | [40] | |||||||
aSouth Africa | A retrospective multicohort study | HB | 2009 – 2013 | SAM | 454 | 6 to 60 months | HIV (n=196) | 24.4% (n=108) | Muzigaba et al, 2017 | [41] | |||||||
aEthiopia | Retrospective | HB | 2012 - 2016 | SAM | 1690 | The majority of the participants were < 2 years | TB (n=107), HIV (n=54) | - | Baraki et al, 2020 | [42] | |||||||
aDemocratic Republic of Congo | Retrospective | HB | 2017 - 2018 | SAM | 633 | 1 month to 18 years | HIV (n=14), malaria (n=33), bacteremia (n=38) | 9.2% (n=58) | Kambale et al, 2020 | [43] | |||||||
aEthiopia | Retrospective cohort study | HB | 2012 – 2019, (may to June 2019) | SAM | 515 | Majority were < 24 months | TB (n=71) | 9% (n=46) | Bitew et al, 2020 | [44] | |||||||
aEthiopia | Retrospective cross-sectional study | HB | 2015 - 2017 | SAM | 205 | 1 month – 14 years | HIV (n=21), TB (n=16), malaria (n=30) | 4.4% (n=9) | Mena et al, 2018 | [45] | |||||||
aEthiopia | Retrospective study | HB | 2013 - 2015 | SAM | 196 | Median age: 12+8.5 months. | TB (n=27), malaria (n=2) | 16% (NS) | Kabeta et al, 2017 | [46] | |||||||
aUganda | Analytical and Descriptive Prospective Cohort Study | HB | July to September 2019 | SAM | 338 | < 5 years | Malaria (n=72), bacteremia (n=23), HIV (n=20), TB (n=17) | 14.5% (49) | Banga et al, 2020 | [47] | |||||||
aEthiopia | Retrospective cohort study | HB | 2015 to 2017 | SAM | 420 | 6 to 59 months | HIV (n=3), TB (n=87), malaria (n=10) | 10.8% (n=41) | Fikrie et al, 2019 | [48] | |||||||
aEthiopia | Cross-sectional study | HB | 2010 to 2012 | SAM | 298 | 2 to 59 months | HIV (n=5) | 11.7% (n=35) | Abeje et al 2016 | [49] | |||||||
aEthiopia | A Retrospective Cohort Study | HB | 2011 to 2013 | SAM | 415 | 0 to 59 months | TB (n=9), HIV (n=17), malaria (n=77) | 28.7% (n=119) | Desta et al, 2015 | [50] | |||||||
aEthiopia | A Retrospective Cohort Study | HB | 2013 to 2016 | Complicated SAM | 259 | 6 to 59 months | TB (n=18), HIV (n=11) | 12.2% (n=37) | Negussie et al, 2020 | [51] | |||||||
aNigeria | Prospective cohort study | HB | 2017 to 2019 | SAM | 100 | Mean age: 14.28 ± 14.04 months | HIV (n=81), TB (n=79) | 7.7% (NS) | Ikobah et al, 2022 | [52] | |||||||
aEthiopia | Retrospective cohort study | HB | 2014 to 2016 | SAM | 253 | 6 to 59 months | TB (n=19) | 5.5% (n=14) | Mekuria et al, 2017 | [53] | |||||||
aUganda | Prospective cohort study | HB | 2014 to 2015 | SAM | 400 | 6 to 59 months | HIV (n=43) | 9.8% (39) | Nabukeera-Barungi et al, 2017 | [54] | |||||||
aEthiopia | Cross-sectional study | HB | 2012 to 2016 | SAM | 401 | 6 to 59 months | TB (n=37), HIV (n=26), malaria (n=13) | 8.5% (n=34) | Desyibelew et al 2017 | [55] | |||||||
aCameroon | Retrospective study | HB | 2006 to 2015 | SAM | 179 | < 15 years | Malaria (n=27) | 15% (n=27) | Chiabi et al, 2016 | [56] | |||||||
aSenegal | Descriptive and analytical cross-sectional study | HB | March to November, 2021 | Complicated SAM | 103 | 6 to 59 months | TB (n=2), HIV (n=6) | 2.9% (n=3) | Ba et al, 2023 | [57] | |||||||
Uganda | Cross sectional study | HB | 2023 - 2024 | SAM | 137 | 6-59 months | TB (n=32) | - | Asiimwe et al, 2024 | [58] | |||||||
aEthiopia | Cross sectional study | HB | Not stated | SAM | 351 | 0.5-14 years | HIV (n=9), TB (n=17), malaria (n=9) | - | Girma et al 2013 | [59] | |||||||
aEthiopia | Retrospective study | HB | 2015 - 2019 | SAM | 454 | 6 – 59 months | HIV (n=15), TB (n=35) | - | Bizuneh et al 2022 | [60] | |||||||
aEthiopia | Retrospective cohort study | OTP | 2016 - 2019 | SAM | 600 | Birth to 59 months | HIV (n=12), TB (n=12) | 2.0% (n=12) | Abate et al 2020 | [61] | |||||||
South Africa | Prospective | HB | 2012 - 2015 | SAM | 82 | 1 month to 10.6 years | HIV (n=82), Bacteria (n=51) | - | Archary et al, 2016 | [62] | |||||||
aEthiopia | A retrospective cohort study | HB | January to February, 2021 | SAM | 162 | 6 – 59 months | Malaria (n=9), HIV (n=12) | 6.8% (n=11) | Aye et al, 2023 | [63] | |||||||
aEthiopia | A prospective cohort study | HB | March to July, 2018 | SAM | 133 | 6 – 59 months | TB (n=24), HIV (n=3), malaria (n=3) | 3.8% (NS) | Adem et al, 2020 | [64] | |||||||
Uganda | A prospective cohort study | HB | 2010 - 2011 | SAM | 74 | 6 months – 5 years | HIV (n=18), malaria (n=7) | 12% (n=9) | Mody et all, 2014 | [65] | |||||||
Ethiopia | A Retrospective Cohort Study | HB | 2015 – 2017 | SAM | 375 | 6 – 59 months | HIV (n=15), TB (n=54), malaria (n=21) | 12.3% (n=43) | Kabthymer et al, 2020 | [66] | |||||||
Malawi | Prospective observational study | HB | 2021 - 2022 | Complicated SAM | 131 | 6 – 59 months | TB (n=4) | - | Vonasek et al, 2024 | [67] | |||||||
Ethiopia | Retrospective cohort study | HB | 2018 - 2022 | SAM | 247 | < 5 years | TB (n=24) | - | Wake et al, 2024 | [68] | |||||||
aEthiopia | Retrospective, Cohort study | HB | 2016 to 2019 | SAM | 476 | < 5 years | HIV (n=31) TB (n=61) |
11.3% (n=54) | Kassaw et al 2021 | [69] | |||||||
Uganda | Prospective cohort study | HB | June to August 2015 | SAM | 122 | Children under 5 years | HIV (n=9) Malaria (n=25) |
- | Nduhukire et al.2020 | [70] | |||||||
Kenya | Retrospective cohort study | HB | 2007-2016 | SAM | 3090 | 5-12yrs | HIV (n=197) | 3.4% (n=132) | Ngari et al, 2021 | [71] | |||||||
Zambia | Cross-sectional study | HB | 19982000 | SAM | 200 | 6 to 24months | HIV (n=106), TB (n=27), bacteremia (n=26), Intesstinal infection [Cryptosporidium parvum (n=47), Isospora belli (n=4), Giardia intestinalis (n=11), Blastocystis hominis (n=4), Microsporidia (n=1), Salmonella spp. (n=35), Shigella spp.(n=4), Vibrio cholerae (n=6), Hookworm (n=3), Ascaris lumbricoides (n=10), Yeast cells (n=74) | 19.5% (39) | Amadi et al, 2001 | [72] | |||||||
Uganda | Prospective cohort study | HB | November 2007 to July 2008 | SAM | 270 | <5yrs | HIV (n=33) | 25% (n=67) | Nwalanga et al 2020 | [73] | |||||||
aSudan | Case control study | HB | 1992-1993 | SAM | 81 | 0 to 5 years | TB (n=8), intestinal parasitic infection (n=24), UTI [(E. coli, (n=6), Proteus species (n=2), Klebsiella species (n=2)] | - | Suliman et al, 2011 | [74] | |||||||
aUganda | Prospective observational study | HB | 2012 - 2013 | SAM | 120 | 6 – 59 months | HIV (n=20) | 14% (n=17) | Rytter et al, 2017 | [75] | |||||||
aEthiopia | Retrospective cohort study | HB | December 10-30, 2021 | SAM | 712 | 6 months to 59 months | TB (n=43), HIV (n=3) |
5.9% | Ahmed et al, 2023 | [76] | |||||||
aGhana | Prospective observational study | HB | 2013 to 2018 | SAM | 601 | 0 to 59 months | HIV (54), TB (n=32), malaria(n=110) | 16.5% (n=99) | Asare et al, 2021 | [77] | |||||||
Zambia | Cohort study | HB | August - December 2009 | Complicated SAM | 430 | 6 months to 59 months | HIV (n=161) TB (n=6) |
40.5% (n=174) | Irena et al 2013 | [78] | |||||||
Uganda | Retrospective observational study | HB | January to December 2017 | Complicated SAM | 330 | 1-5yrs | HIV (n=86) | 22% (70) | Muwanguzi et al, 2021 | [79] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated